Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors
Clinical Pharmacokinetics · 2024-04 · 63 (4) · 423-438
DOI: 10.1007/s40262-024-01369-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 12.04.2024. Verfasst von Mei Tang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoconjugates, Nectins. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute Cancer Center Support, Astellas Pharma, Inc..
Abstract (Originalsprache)
Enfortumab vedotin is an antibody-drug conjugate comprised of a human monoclonal antibody directed to Nectin-4 and monomethyl auristatin E (MMAE), a microtubule-disrupting agent. The objectives of this review are to summarize the clinical pharmacology of enfortumab vedotin monotherapy and demonstrate that the appropriate dose has been selected for clinical use. Pharmacokinetics (PK) of enfortumab vedotin (antibody-drug conjugate and total antibody) and free MMAE were evaluated in five clinical trials of patients with locally advanced or metastatic urothelial carcinoma (n = 748). Intravenous enfortumab vedotin 0.5-1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle showed linear, dose-proportional PK. No significant differences in exposure or safety of enfortumab vedotin and free MMAE were observed in mild, moderate, or severe renal impairment versus normal renal function. Patients with mildly impaired versus normal hepatic function had a 37% increase in area under the concentration-time curve (0-28 days), a 31% increase in maximum concentration of free MMAE, and a similar adverse event profile. No clinically significant PK differences were observed based on race/ethnicity with weight-based dosing, and no clinically meaningful QT prolongation was observed. Concomitant use with dual P-glycoprotein and strong cytochrome P450 3A4 inhibitors may increase MMAE exposure and the risk of adverse events. Approximately 3% of patients developed antitherapeutic antibodies against enfortumab vedotin 1.25 mg/kg. These findings support enfortumab vedotin 1.25 mg/kg monotherapy on days 1, 8, and 15 of a 28-day cycle. No dose adjustments are required for patients with renal impairment or mild hepatic impairment, or by race/ethnicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., 2375 Waterview Drive, Northbrook, IL, 60062-6111, USA.
- Clinical Pharmacology Oncology, Pfizer Inc., 181 Oyster Point Boulevard, South San Francisco, CA, 94080, USA. amit.garg@pfizer.com.
- Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Therapeutic Area-Oncology, Astellas Pharma Global Development, Astellas Pharma, Inc., Northbrook, IL, USA.
- Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan.
- Analysis and Pharmacokinetics Research Laboratories, Drug Discovery Research, Astellas Pharma, Inc, Tsukuba, Japan.
ORCID-Profile: Srinivasu Poondru
Förderung
- NCI NIH HHS
- National Cancer Institute Cancer Center Support
- Astellas Pharma, Inc.
- Seagen Inc.
Zitieren
APA
Tang, M., Garg, A., Bonate, P. L., Rosenberg, J. E., Matsangou, M., Kadokura, T., Yamada, A., Choules, M., Pavese, J., Nagata, M., Tenmizu, D., Koibuchi, A., Heo, N., Wang, L., Wojtkowski, T., Hanley, W. D., & Poondru, S. (2024). Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Clinical Pharmacokinetics, 63(4), 423-438. https://doi.org/10.1007/s40262-024-01369-0
Vancouver
Tang M, Garg A, Bonate PL, Rosenberg JE, Matsangou M, Kadokura T, et al. Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Clinical Pharmacokinetics. 2024;63(4):423-438. doi:10.1007/s40262-024-01369-0
BibTeX
@article{Tang2024,
author = {Tang, Mei and Garg, Amit and Bonate, Peter L and Rosenberg, Jonathan E and Matsangou, Maria and Kadokura, Takeshi and Yamada, Akihiro and Choules, Mary and Pavese, Janet and Nagata, Masanori and Tenmizu, Daisuke and Koibuchi, Akira and Heo, Nakyo and Wang, Lu and Wojtkowski, Tomasz and Hanley, William D and Poondru, Srinivasu},
title = {Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors},
journal = {Clinical Pharmacokinetics},
year = {2024},
volume = {63},
number = {4},
pages = {423--438},
doi = {10.1007/s40262-024-01369-0}
}
EUVIMED